Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Express Scripts
Medtronic
Harvard Business School
Boehringer Ingelheim

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR EXJADE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Exjade

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00171301 Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) Completed Novartis Pharmaceuticals Phase 4 2005-06-01 To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available. To evaluate the long-term safety and efficacy of deferasirox by measuring treatment success, change in liver iron content (LIC) and change in serum ferritin levels. Safety was mainly assessed by incidence of adverse events (AEs)and clinically significant lab parameters.
NCT00235391 Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload Completed Novartis Pharmaceuticals Phase 3 2005-10-01 This is an open-label, non-randomized, multi-center trial designed to provide expanded access of deferasirox to patients with congenital disorders of red blood cells and chronic iron overload from blood transfusions who cannot adequately be treated with locally approved iron chelators.
NCT00419770 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Astellas Pharma Inc Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
NCT00419770 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Gilead Sciences Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
NCT00419770 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Novartis Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
NCT00419770 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed Los Angeles Biomedical Research Institute Phase 2 2007-10-01 The purpose of this study is to determine if the addition of the medication, deferasirox, to standard antifungal therapy for the infection, mucormycosis, is safe and effective
NCT00452660 Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load Completed Hadassah Medical Organization Phase 4 2007-05-01 Certain percentage of MDS patients develop iron overload. Iron is known to participate in intracellular reactions that generate free radicals, inducing oxidative stress and apoptosis, which was found to be increased in MDS patients and consequently resulted in ineffective hematopoiesis. The aim of this study is to evaluate the antioxidant effect of the oral iron chelator Deferasirox -Exjade in low risk MDS patients with iron over load by evaluating changes in several oxidative stress parameters Certain percentage of MDS patients develop iron overload.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Exjade

Condition Name

Condition Name for Exjade
Intervention Trials
Myelodysplastic Syndromes 6
Iron Overload 5
Thalassemia 3
Sickle Cell Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Exjade
Intervention Trials
Iron Overload 15
Thalassemia 10
Preleukemia 8
Myelodysplastic Syndromes 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Exjade

Trials by Country

Trials by Country for Exjade
Location Trials
United States 49
Italy 6
Germany 3
Canada 3
Egypt 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Exjade
Location Trials
California 5
Pennsylvania 4
Texas 3
New York 3
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Exjade

Clinical Trial Phase

Clinical Trial Phase for Exjade
Clinical Trial Phase Trials
Phase 4 9
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 16
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Exjade
Clinical Trial Phase Trials
Completed 10
Unknown status 6
Recruiting 5
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Exjade

Sponsor Name

Sponsor Name for Exjade
Sponsor Trials
Novartis Pharmaceuticals 9
Novartis 6
Ann & Robert H Lurie Children's Hospital of Chicago 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Exjade
Sponsor Trials
Other 51
Industry 20
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.